Comparison of cytogenetic damage in groups of patients with myeloproliferative neoplasms, depending on the presence or absence of V617F mutation in JAK2 gene



Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Myeloproliferative neoplasms are diseases characterized by clonal proliferation of myeloid bone marrow. At present, it describes a number of genetic markers myeloproliferative neoplasms, such as JAK2v617f. However the nature of violations in the progenitor cells is still not clear. In this study, a comparative analysis of cytogenetic damage in patients with myeloproliferative neoplasms with a mutation JAK2v617f and without this damage. The study showed that differences in the number and diversity of received clonal damage in both groups was not significant. Given the small number of patients with clonal cells, it can be assumed that cytogenetic analysis diagnostically significant.

Texto integral

Acesso é fechado

Sobre autores

S. Kolubaeva

S.M. Kirov Military Medical Academy

Saint Petersburg, Russia

A. Polyakov

S.M. Kirov Military Medical Academy

Saint Petersburg, Russia

A. Kissel

S.M. Kirov Military Medical Academy

Saint Petersburg, Russia

L. Myakoshina

S.M. Kirov Military Medical Academy

Saint Petersburg, Russia

N. Viktorova

S.M. Kirov Military Medical Academy

Saint Petersburg, Russia

S. Ushanov

S.M. Kirov Military Medical Academy

Saint Petersburg, Russia

A. Titova

S.M. Kirov Military Medical Academy

Saint Petersburg, Russia

A. Ivanov

S.M. Kirov Military Medical Academy

Saint Petersburg, Russia

Ya. Noskov

S.M. Kirov Military Medical Academy

Saint Petersburg, Russia

S. Bologov

S.M. Kirov Military Medical Academy

Saint Petersburg, Russia

S. Voronin

S.M. Kirov Military Medical Academy

Saint Petersburg, Russia

Bibliografia

  1. Tefferi A., Vardiman J.W. Classification and of myeloproliferative neoplasms: Tye 2008 World Health Organization criteria and point of care diagnostic algotryms. Leukemia 2008; 22: 14-22.
  2. Heim S., Mitelman F. Chronic myeloproliferative neoplasms. In: Cancer Cytogenetics, third edition. Canada: Wiley-Blackwell; 2009; p. 209-32.
  3. Kaushansky K. The chronic myeloproliferative disorders and mutation of JAK2: Damesh ek's 54 year old speculation comes of age. Best Pract. Res. Clin. Haematol. 2007; 20: 5-12.
  4. Scott L.M., Tong W., Levine R.L. et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 2007; 356: 459-68.
  5. Nussenzveig R.H., Swierczek S.I., Jelinek J. et al. Polycythemia vera is not initiated by JAK V617F mutation. Exp. Hematol. 2007; 35: 32-8.
  6. Theocharides A., Boissinot M., Girodon F. et al. Leukemic blasts in transformed JAK2V617F-positive myeloproliferative disorders are frequently negative for the JAK2V617F mutation. Blood 2007; 110: 375-79.
  7. Pietra D., Li S., Brisci A. et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2007; 111: 1686-89.
  8. Eds. L. Shaffer, N. Tommerup. An international system for human cytogenetic nomenclature. In: Recommendations of International Standing Commitee on Human Cytogenetic Nomenclature. Basel: S. Karger; 2013.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Eco-Vector, 2016


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies